These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 1471633)
1. Benefits to hospitals of sole home infusion therapy providers. Enriquez N; Conte R Am J Hosp Pharm; 1992 Nov; 49(11):2707-8. PubMed ID: 1471633 [No Abstract] [Full Text] [Related]
2. Impact of home infusion therapy on the Colorado Medicaid program budget. Culbertson VL; Rhodes RS; Hill EP; Rhodes PJ Am J Hosp Pharm; 1988 Jun; 45(6):1346-9. PubMed ID: 3137814 [TBL] [Abstract][Full Text] [Related]
3. A clinical productivity management system for home infusion therapy. Grace LA; Illian AF; Rivers MP J Intraven Nurs; 1993; 16(4):251-60. PubMed ID: 8410482 [TBL] [Abstract][Full Text] [Related]
4. Home infusion therapy meets managed care: confrontation or cooperation. Winters RW Med Interface; 1994 Jul; 7(7):72-4, 85. PubMed ID: 10135994 [TBL] [Abstract][Full Text] [Related]
5. Home infusion therapy: comparison of costs for intravenous immunoglobulin. Bielory L; Long GC N J Med; 1993 Jul; 90(7):512-5. PubMed ID: 8355890 [TBL] [Abstract][Full Text] [Related]
6. Hospital selection of home infusion therapy companies as preferred providers. Rich DS; Ayers N Am J Hosp Pharm; 1992 Jul; 49(7):1707-12. PubMed ID: 1621728 [TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Williams DN; Bosch D; Boots J; Schneider J Clin Ther; 1993; 15(1):169-79; discussion 168. PubMed ID: 8458046 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness issues for home i.v. therapy in the United States. Allen R Hosp Formul; 1993 Jan; 28 Suppl 1():37-40. PubMed ID: 10123837 [TBL] [Abstract][Full Text] [Related]
10. Medicare program; changes to the return on equity capital provisions and the exception from the cost limits for newly-established home health agencies--HCFA. Proposed rule. Fed Regist; 1986 Feb; 51(34):6139-45. PubMed ID: 10300574 [TBL] [Abstract][Full Text] [Related]
11. Cost implications of home care on serious infections. Rubinstein E Hosp Formul; 1993 Jan; 28 Suppl 1():46-50. PubMed ID: 10123839 [TBL] [Abstract][Full Text] [Related]
12. Home health care costs: intravenous immunoglobulin home infusion therapy. Bielory L; Long GC Ann Allergy Asthma Immunol; 1995 Mar; 74(3):265-8. PubMed ID: 7889384 [TBL] [Abstract][Full Text] [Related]
13. Managing Blue Cross & Blue Shield benefits for high-tech home care. Lange MH Caring; 1986 Sep; 5(9):58-60. PubMed ID: 10278849 [No Abstract] [Full Text] [Related]
14. Pharmacist facilitation of a home IV therapy treatment program. Sorrentino AP; Tietze KJ Hosp Pharm; 1985 Jul; 20(7):513-4, 517. PubMed ID: 10272731 [TBL] [Abstract][Full Text] [Related]
15. Home iv therapy benefit of the Catastrophic Coverage Act: it's impact on home care providers. Marren J; Rodgers B; Dishon M Pride Inst J Long Term Home Health Care; 1989; 8(3):15-8. PubMed ID: 10303818 [No Abstract] [Full Text] [Related]
16. The provider's perspective. Appreciating the true costs of home infusion. Ussery C Contin Care; 1993 Jun; 12(5):36, 42. PubMed ID: 10148818 [No Abstract] [Full Text] [Related]
17. Hospital-based home health care: gaining a competitive advantage where everyone benefits. O'Donnell KP Am J Hosp Pharm; 1984 Jan; 41(1):147-8. PubMed ID: 6421155 [No Abstract] [Full Text] [Related]